News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
7.94 crore doses were made available to the states in May 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
